
CLAIMS


1. A salt form of Compound 1



(Compound 1)

wherein the salt form is selected from the group consisting of a besylate salt, a tosylate salt, napadisylate, a napsylate, a camsylate salt, and an edisylate salt.

2. The salt form according to Claim 1, which is a besylate salt Form I form of Compound 1



(Compound 1),

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.9, 13.3, 16.2, 17.6 and 21.8 degrees 2θ (± 0.2 degrees 2θ).

3. The besylate salt Form 1 according to claim 2, further characterized by XRPD peaks at 6.6, 7.6, 14.5, 16.2, and 28.2 degrees 2θ (± 0.2 degrees 2θ)

4. The besylate salt Form 1 according to claim 2, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1.

5. The besylate salt Form 1 according to any one of claims 2 to 4, further characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at around 207.2 °C.

6. The besylate salt Form I, according to any one of claims 2 to 4, further characterized by a melting point onset of about 200.6 °C as determined by differential scanning calorimetry thermogram (DSC).

7. The besylate salt Form I, according to any one of claims 2 to 4, wherein said DSC thermogram is substantially in accordance with FIG. 2.

8. The besylate salt Form I, according to any one of claims 2 to 7, further characterized by a weight loss of about 0.14% upon heating to around 202.9 °C, as measured by thermal gravimetric analysis (TGA).

9. The besylate salt Form I, according to any one of claims 2 to 7, further characterized a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 2.

10. The besylate salt Form I, according to any one of claims 2 to 9, further characterized by a weight gain of about 0.5 % after undergoing a dynamic vapor sorption cycle from about 0% relative humidity (RH) to about 75% RH at 25 ºC.

11. The besylate salt Form I, according to any one of claims 2 to 9, further characterized by a weight gain of about 0.73 % after undergoing a dynamic vapor sorption cycle from about 5% relative humidity (RH) to about 95% RH at 25 ºC.

12. The besylate salt Form I, according to any one of claims 2 to 9, having a dynamic vapor sorption profile substantially as shown in FIG. 3.

13. The besylate salt Form I, according to any one of claims 2 to 12, further characterized by a scanning electron microscopy (SEM) image having predominantly prismatic or anhedral particles.


14. The besylate salt Form I, according to claim 13, wherein particle sizes are about 1 μm to 73 μm as determined by scanning electron microscopy (SEM).

15. The besylate salt Form I, according to any one of claims 2 to 12, further characterized by scanning electron microscopy (SEM) image substantially in accordance with FIG. 4.

16. The besylate salt Form I, according to any one of claims 2 to 15, further characterized by particles ranging in size from about 2.5 to 83 μm as determined by polarized light microscope (PLM).

17. The besylate salt Form I, according to any one of claims 2 to 15, further characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 5.

18. The salt form according to Claim 1, which is a besylate salt Form II of Compound 1




(Compound 1),

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 3.6, 7.1, 12.3, 12.8, and 16.7 degrees 2θ (± 0.2 degrees 2θ).

19. The besylate salt Form II, according to claim 18, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 6.

20. The salt form according to Claim 1, which is a tosylate salt Form I of Compound 1




(Compound 1)

in a single crystalline form which is substantially free of other crystalline or amorphous forms,

characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.6, 10.8, 13.1, 16.5, 19.7, 21.6 degrees 2θ (± 0.2 degrees 2θ).

21. The tosylate salt Form I according to claim 20, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 8.

22. The salt form according to Claim 1, which is a napadisylate salt Form I form of Compound 1




(Compound 1)

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.5, 7.0, 12.4, 14.7, 15.2, and 18.0 degrees 2θ (± 0.2 degrees 2θ).

23. The napadisylate salt Form I according to claim 22, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 13.

24. The salt form according to Claim 1, which is a napsylate salt Form I form of Compound 1




(Compound 1),

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.5, 7.7, 10.4, 12.9, and 16.1 degrees 2θ (± 0.2 degrees 2θ).

25. The napsylate salt Form I according to claim 24, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 18.

26. The salt form according to Claim 1, which is a camsylate salt Form I form of Compound 1




(Compound 1),

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.3, 7.9, 10.8, 12.2, and 16.1 degrees 2θ (± 0.2 degrees 2θ).

27. The camsylate salt Form I according to claim 26, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 23.

28. The salt form according to Claim 1, which is an edisylate salt Form I form of Compound 1



(Compound 1),

in a single crystalline form which is substantially free of other crystalline or amorphous forms, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 3.4, 5.6, 12.9, 15.3, 18.1, and 20.8 degrees 2θ (± 0.2 degrees 2θ).

29. The edisylate salt Form I according to claim 28, characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 28.

30. A pharmaceutical composition comprising a salt form of Compound 1 according to any one of claims 1 to 29 and at least one pharmaceutically acceptable excipient.

31. An aqueous suspension comprising a salt form of Compound 1 according to any one of claims 1 to 29, and at least one excipient.

32. An injectable or infusible solution comprising Compound 1 and at least one wetting agent or solvent, wherein the injectable or infusible solution is obtainable using a salt form of Compound 1 according to any one of claims 1 to 29.

33. Use of a salt form of Compound 1 according to any one of claims 1 to 29 in the manufacture of a medicament for the treatment of a disease or disorder involving pathologic activation of C5a receptors, wherein the disease or disorder involving pathologic activation of C5a receptors is selected from the group consisting of an autoimmune disorder, an inflammatory disorder, a cardiovascular disorder, a cerebrovascular disorder, diseases of vasculitis, HIV infection and AIDS, a neurodegenerative disorder, and cancer.